Ovarian Cancer

The "Incessant Ovulation" Hypothesis and Epithelial Ovarian Cancer Development

• During each menstrual cycle, the ovarian surface epithelium undergoes rupture and repair, subjecting cells to repeated cycles of proliferation and potential mutagenic events
• This repetitive trauma creates a permissive environment for malignant transformation, with cumulative risk increasing with total number of lifetime ovulations
• Nulliparity, late menarche, and early menopause alter the frequency of ovulatory cycles, directly correlating with cancer risk
• In contrast, pregnancy and oral contraceptive use suppress ovulation, explaining the protective effects of these factors
• The incessant ovulation hypothesis explains why factors that reduce cumulative ovulatory cycles demonstrate protective effects, though recent evidence suggests additional mechanisms beyond simple epithelial proliferation

High-Grade Serous Carcinoma (HGSC) - Most Common Subtype (~70% of EOC)

• TP53 mutations occur in >95% of HGSC cases, representing the initiating event that disrupts both cell cycle checkpoints (G1/S transition via p21-CDK inhibition) and apoptotic pathways
• Loss of p53 function eliminates critical DNA damage checkpoints, allowing cells with chromosomal instability (CIN) to survive and proliferate
• BRCA1/BRCA2 mutations (present in 15-20% of HGSC) impair homologous recombination (HR) DNA repair pathways, leading to accumulation of chromosomal aberrations and genomic instability
• BRCA-mutant tumors develop platinum sensitivity and respond dramatically to PARP inhibitors, which trap PARP on damaged DNA and convert single-strand breaks into lethal double-strand breaks; the mechanism exploits synthetic lethality—tumors already deficient in HR cannot tolerate additional PARP inhibition
• Copy number alterations (especially amplification of MYC and chromosome 8q) drive oncogenic signaling and proliferation in HGSC
• The genomic instability characteristic of HGSC, while promoting malignant progression, paradoxically creates therapeutic vulnerability to DNA-damaging agents and homologous recombination-targeting drugs

Low-Grade Serous Carcinoma (LGSC) and Mutation-Driven Subtypes

• LGSC frequently harbors KRAS or BRAF mutations (typically mutually exclusive), driving constitutive MAPK pathway activation
• These tumors characteristically demonstrate slow growth kinetics and relative resistance to conventional chemotherapy, but sensitivity to targeted MAPK inhibitors (e.g., selumetinib for KRAS-mutant tumors)
• Endometrioid and clear cell subtypes often carry ARID1A mutations (40-50%), PIK3CA mutations, and PTEN loss, activating PI3K/AKT/mTOR signaling
• These histological subtypes typically present at earlier stages than HGSC but carry unique chemotherapy resistance patterns and benefit from PI3K/mTOR-targeted approaches

Molecular Classification and Therapeutic Implications

• The Cancer Genome Atlas (TCGA) and subsequent studies identified four molecular subtypes: proliferative (high MYC), differentiated (endometrioid/mucinous-like expression), immunoreactive (high immune infiltration), and mesenchymal (EMT activation, stromal enrichment)
• Homologous Recombination Deficiency (HRD) status encompasses both BRCA mutations and BRCAness phenotypes (BRCA1 promoter methylation, RAD51C/RAD51D loss), affecting 50-60% of HGSC and predicting exceptional response to platinum and PARP inhibition
• Tumors with intact HR repair demonstrate platinum resistance and poor prognosis, requiring alternative therapeutic strategies

Spread and Dissemination Mechanisms

• Ovarian cancer characteristically spreads via direct peritoneal seeding (explaining the stage III classification for even small-volume peritoneal involvement), creating a peritoneal-based disease that challenges surgical resection
• Ascites accumulation results from increased vascular permeability due to VEGF and IL-6 production, combined with impaired lymphatic drainage and peritoneal implant formation
• Transcoelomic spread via peritoneal fluid dissemination occurs early, explaining why so many patients present with advanced disease despite primary tumor remaining relatively small
• Lymphatic spread to retroperitoneal nodes (especially para-aortic nodes) indicates stage IIIC disease and requires comprehensive surgical staging

BRCA1/BRCA2 Germline Mutations

• BRCA1 and BRCA2 mutations confer 35-45% and 10-20% lifetime risks of ovarian cancer, respectively (compared to ~1% general population risk)
• These mutations should be screened for in all patients diagnosed with ovarian cancer, regardless of age or family history, given substantial implications for treatment, prognosis, and family planning
• Ashkenazi Jewish ancestry increases prevalence of specific BRCA mutations (1 in 40 vs. 1 in 300 in general population)
• BRCA-mutant ovarian cancers demonstrate superior chemotherapy response and exceptional benefit from PARP inhibition, fundamentally altering treatment strategy
• Homologous recombination deficiency (HRD) testing can identify BRCAness phenotypes in BRCA-wild-type tumors (~20-30% of cases), which also benefit from PARP inhibitor therapy

Reproductive and Hormonal Factors

• Nulliparity increases ovarian cancer risk by 1.5-3-fold; each pregnancy reduces cumulative risk by approximately 10-15%, with protective effect most pronounced for cancers diagnosed before age 60
• Late menarche (>13 years) and early menopause (<45 years) both reduce cumulative ovulatory cycles and lower risk
• Oral contraceptive use reduces risk by 30-50% through suppression of ovulation; protective effect persists 15+ years after discontinuation and increases with duration of use (up to 50% reduction with >10 years use)
• Hormone replacement therapy (HRT) demonstrates modest increased risk (1.2-1.3 fold) in observational studies, though causality remains debated
• Infertility itself, independent of treatment, increases risk, potentially reflecting shared underlying pathophysiology or surveillance bias

Age and Demographic Factors

• Peak incidence occurs at age 55-65 years, with <10% of cases presenting before age 35 years
• Epithelial ovarian cancer is predominantly a disease of postmenopausal women, whereas germ cell tumors and sex cord-stromal tumors present in younger populations
• Northern European ancestry demonstrates higher incidence than Asian or African ancestry

Family History and Hereditary Syndromes

• Hereditary breast and ovarian cancer (HBOC) syndrome accounts for 5-10% of epithelial ovarian cancers; families with ≥2 relatives with breast/ovarian cancer under age 50 warrant genetic counseling
• Lynch syndrome (mismatch repair gene mutations: MLH1, MSH2, MSH6, PMS2) carries elevated ovarian cancer risk (~8-12% lifetime) alongside colorectal and endometrial cancer risk
• Familial adenomatous polyposis (FAP) carries modest ovarian cancer risk elevation

Other Established Risk Factors

• Obesity (BMI >30 kg/m²) increases risk 1.2-1.5 fold, with mechanism related to elevated estrogen production in adipose tissue and chronic inflammation
• Endometriosis, particularly atypical endometriosis, associates with 2-3 fold increased risk of clear cell and endometrioid subtypes, possibly through shared ARID1A mutations and chronic inflammation
• Prior history of breast or colorectal cancer increases ovarian cancer risk through both genetic predisposition (BRCA mutations) and field effect carcinogenesis
• Talc exposure (particularly from perineal use in douching) carries epidemiological evidence for modest risk increase, though causality remains controversial and is subject of ongoing litigation

Protective Factors

• Breastfeeding duration >3 months cumulatively reduces risk
• Tubal ligation and hysterectomy reduce risk by 20-35%, possibly through altered peritoneal inflammatory milieu or reduced retrograde menstruation

Early-Stage Disease (Stages I-II) - Often Asymptomatic

Cardinal Presenting Symptoms - Advanced Disease (Stages III-IV)

• Abdominal and Pelvic Pain: Caused by peritoneal implants, adhesions, and visceral involvement; often constant and progressive over weeks to months, typically lower abdominal/pelvic location but can be epigastric if upper abdominal disease present. The pain physiology reflects both visceral nociception from tumor burden and somatic pain from peritoneal irritation and parietal peritoneum involvement.

• Abdominal Distension and "Bloating": Ascites accumulation drives abdominal swelling, frequently accompanied by early satiety (from gastric compression or peritoneal involvement) and weight gain despite poor appetite. Ascites pathophysiology involves VEGF-mediated increased vascular permeability, IL-6-driven fluid accumulation, and impaired lymphatic drainage. This symptom is frequently initially attributed to functional dyspepsia or irritable bowel syndrome, delaying diagnosis by months.

• Gastrointestinal Symptoms: Constipation (from peritoneal disease compressing bowel), diarrhea (from mucosal involvement), nausea, and anorexia. These symptoms result from peritoneal irritation, mechanical bowel obstruction from implants, or paraneoplastic effects. In advanced disease, bowel obstruction from peritoneal carcinomatosis represents a treatment-limiting complication.

• Vaginal Bleeding or Abnormal Discharge: Most significant in postmenopausal women, where any vaginal bleeding warrants evaluation for malignancy. Premenopausal patients may present with abnormal menses or intermenstrual bleeding from endometrial involvement or hormonally-active tumors.

• Urinary Symptoms: Urgency, frequency, or dysuria from bladder involvement or peritoneal irritation; flank pain may indicate ureteral obstruction from peritoneal disease.

• Constitutional Symptoms: Unintentional weight loss (reflecting cachexia from cytokine production and poor oral intake), fatigue (from anemia of chronic disease and paraneoplastic effects), and night sweats indicate advanced disease.

Physical Examination Findings

• Pelvic Mass: Fixed, irregular, nodular mass often palpable on bimanual examination; presence of bilateral masses or involvement of other pelvic structures carries ominous prognostic implications

• Ascites: Shifting dullness to percussion, fluid thrill on abdominal examination, or visible abdominal distension with visible veins; presence of tense ascites indicates advanced disease

• Peritoneal Nodules: Nodular peritoneal implants palpable on abdominal examination (particularly along peritoneal surfaces and omentum)

• Hepatomegaly or Liver Nodules: Suggests hepatic metastases or peritoneal involvement of liver capsule

• Supraclavicular or Inguinal Lymphadenopathy: Indicates distant nodal metastases and stage IV disease

• Pleural Effusion or Pulmonary Findings: Suggest stage IV disease with pulmonary involvement

Important Clinical Variants and Special Presentations

• Germ Cell Tumors (typically age 15-40): Present with acute pelvic pain from hemorrhage or rupture; often accompanied by markedly elevated β-hCG and/or AFP levels; may present as pelvic mass with precocious puberty (estrogen-secreting tumors) or virilization (androgen-secreting stromal tumors)

• Sex Cord-Stromal Tumors: Often hormonally active, presenting with abnormal uterine bleeding, irregular menses, or virilization; frequently diagnosed at earlier stages due to symptom-driven evaluation

• Low-Grade Serous Carcinoma: May present incidentally as small adnexal mass; characteristically present at stage I-II with slow growth kinetics, but near-uniform recurrence over time with different treatment responsiveness than HGSC

• Clear Cell and Endometrioid Subtypes: Often stage I-II at presentation (more favorable prognosis initially), but platinum resistance in advanced cases limits treatment options; association with endometriosis may provide diagnostic clue

• Mucinous Tumors: Large, often present as massive adnexal masses; frequently stage I at diagnosis; unusual for epithelial mucinous tumors to be primary ovarian (most are metastatic appendiceal adenocarcinomas), requiring careful assessment of primary site

• Acute Presentation: Ovarian torsion (if tumor on pedicle), peritoneal hemorrhage from tumor rupture, or acute bowel obstruction can mandate urgent surgical intervention

History and Risk Stratification

Serum Tumor Markers

• CA-125 (Cancer Antigen 125): Most widely used marker; normal value <35 U/mL. Elevated in 80-90% of advanced epithelial ovarian cancers but in only 50% of stage I disease, limiting early detection utility. CA-125 elevation is not specific (elevated in endometriosis, menstruation, fibroids, peritoneal inflammation, hepatic cirrhosis, pancreatitis); therefore, isolated CA-125 elevation in premenopausal women should not prompt aggressive evaluation without imaging correlation. CA-125 kinetics (serial measurements) more useful than absolute values for treatment response assessment. In postmenopausal women with pelvic mass and CA-125 >200 U/mL, ovarian cancer risk exceeds 95%.

• Human Chorionic Gonadotropin (β-hCG): Markedly elevated (often >1000 IU/L) in germ cell tumors and some non-gestational trophoblastic tumors; when elevated, indicates presence of trophoblastic differentiation

• Alpha-Fetoprotein (AFP): Elevated in germ cell tumors with yolk sac differentiation (characteristic of dysgerminoma); normal range <10 ng/mL

• Inhibin: Useful marker in granulosa cell tumors of sex cord-stromal origin; not routinely measured in epithelial ovarian cancer

Imaging Studies

• Pelvic Ultrasound (Transvaginal and Transabdominal): First-line imaging modality for evaluating adnexal masses. Can characterize cystic vs. solid components, vascularity, and presence of free fluid. Sensitivity approaches 90% for detection of adnexal masses; specificity for malignancy is enhanced by presence of irregular septations, thick walls, solid components, vascularity on color Doppler, or restricted diffusion on D

Immediate stabilisation (advanced/symptomatic presentation)

• Malignant bowel obstruction: bowel rest, nasogastric decompression, IV fluids, and antiemetics; surgical or endoscopic diversion only after gynecologic oncology assessment, since diffuse carcinomatosis often precludes resection.
• Tense ascites or symptomatic pleural effusion: therapeutic paracentesis/thoracentesis relieves dyspnea and provides cytology, but cytology alone is not a substitute for surgical staging.
• Venous thromboembolism: anticoagulate; low-molecular-weight heparin or a DOAC per oncology VTE guidance (ASCO/NCCN).

Definitive management — surgery first when feasible

• Per the NCCN Ovarian Cancer guideline, primary treatment is comprehensive surgical staging with maximal cytoreduction by a gynecologic oncologist: total hysterectomy with bilateral salpingo-oophorectomy, omentectomy, peritoneal washings, multiple peritoneal biopsies, and retroperitoneal nodal evaluation.
• The goal is R0 (no visible residual disease) — residual tumor volume is the strongest surgically modifiable prognostic factor, because chemotherapy penetrates bulky, poorly vascularized implants poorly.
• Neoadjuvant chemotherapy with interval debulking is preferred (ASCO/SGO guidance) when disease is unresectable to R0 or the patient's performance status prohibits extensive surgery; biopsy confirmation of invasive carcinoma is required first.
• Fertility-sparing unilateral salpingo-oophorectomy with staging is acceptable in young women with stage IA disease or malignant germ cell tumors.

Systemic therapy

• Platinum agent + taxane (carboplatin plus paclitaxel) is the first-line doublet for essentially all epithelial disease beyond stage IA/IB grade 1, which may be observed.
• Anti-VEGF monoclonal antibody (bevacizumab) may be added and continued as maintenance in high-risk/advanced disease.
• PARP inhibitor maintenance (olaparib, niraparib) after response to platinum — greatest benefit with BRCA mutation or HRD, exploiting synthetic lethality.
• Germ cell tumors: bleomycin/etoposide/cisplatin (BEP).

Disease-related

• Malignant bowel obstruction (emergency): peritoneal implants encase and kink bowel loops; signals itself as vomiting, obstipation, and air-fluid levels on upright film. The leading cause of death in advanced disease.
• Recurrent malignant ascites: VEGF-driven capillary leak plus lymphatic obstruction; rapidly reaccumulating distension after paracentesis.
• Ureteral obstruction/hydronephrosis: retroperitoneal or pelvic sidewall disease; rising creatinine with flank pain, dilated collecting system on imaging — decompress urgently if bilateral or infected.
• Pleural effusion: transdiaphragmatic spread; a cytology-positive effusion defines stage IV.
• Venous thromboembolism (emergency if PE): tumor tissue factor and mucin-driven hypercoagulability (Trousseau syndrome); unexplained dyspnea or unilateral leg swelling.
• Cachexia and protein-calorie malnutrition: cytokine-mediated catabolism plus early satiety.

Treatment-related

• Febrile neutropenia (emergency): chemotherapy myelosuppression at the nadir; single fever in a neutropenic patient mandates immediate broad-spectrum antipseudomonal beta-lactam (e.g., cefepime) per IDSA neutropenic fever guidance.
• Carboplatin hypersensitivity/anaphylaxis (emergency): IgE-mediated, characteristically appearing after multiple lifetime platinum cycles — flushing, bronchospasm, hypotension mid-infusion; treat with intramuscular epinephrine 0.3 mg.
• Paclitaxel peripheral neuropathy: microtubule stabilization in axons; stocking-glove numbness prompting dose reduction.
• Cisplatin nephrotoxicity, ototoxicity, and hypomagnesemia: proximal tubular and cochlear hair cell injury — a reason carboplatin is preferred.
• Bevacizumab toxicities: hypertension and proteinuria from impaired endothelial nitric oxide/podocyte VEGF signaling; GI perforation and impaired wound healing (emergency) presenting as acute abdomen with free air.
• PARP inhibitor myelosuppression: thrombocytopenia and anemia (notable with niraparib); long-term risk of therapy-related MDS/AML.
• Surgical menopause: post-oophorectomy vasomotor symptoms, bone loss, and sexual dysfunction in premenopausal women.

• **Postmenopausal woman with bloating, early satiety, ascites, and omental caking on CT**: the single best next step is referral to a gynecologic oncologist for surgical staging and cytoreduction — not percutaneous biopsy of a resectable mass, which risks peritoneal spillage.
• CA-125 is not a screening test. The USPSTF gives screening for ovarian cancer in asymptomatic average-risk women a grade D recommendation (CA-125 plus transvaginal ultrasound); its value is in monitoring treatment response and surveillance, not detection.
• Every woman with epithelial ovarian cancer gets germline genetic testing, regardless of age or family history (NCCN) — results drive PARP inhibitor eligibility and cascade testing of relatives.
• Risk-reducing bilateral salpingo-oophorectomy after childbearing is the intervention that most reduces ovarian cancer mortality in BRCA1/2 carriers; it is offered earlier for BRCA1 than BRCA2 given earlier onset (NCCN).
• Histology buzzwords: psammoma bodies → serous carcinoma; Call-Exner bodies + inhibin + precocious puberty/postmenopausal bleeding → granulosa cell tumor; Schiller-Duval bodies + AFP → yolk sac tumor; LDH + a young woman with a solid ovarian mass → dysgerminoma; pseudomyxoma peritonei → appendiceal mucinous neoplasm; bilateral signet-ring metastases → Krukenberg tumor from gastric primary.
• Meigs syndrome = benign ovarian fibroma + ascites + right pleural effusion; ascites plus a pelvic mass is not automatically malignancy, and the effusion resolves after tumor removal.
• The distractor to avoid: an elevated CA-125 in a premenopausal woman is frequently benign (endometriosis, fibroids, PID, menses, cirrhosis) — imaging correlation, not laparotomy, comes first.
• Platinum-free interval defines the regimen: a long interval predicts response to re-challenge with a platinum doublet; a short interval means platinum-resistant disease and a switch to non-platinum single-agent therapy.